Dr. Anke Caßing

Principal / Authorized Signatory

Dr. Anke Caßing

Principal / Authorized Signatory

Dr. Anke Caßing has many years of experience in strategic marketing and business development in medical technology, biotechnology and in pharmaceutics. She holds a doctorate in biology and studied economics. Before joining the HTGF, she developed the product portfolios of international companies ensuring their future growth.


+49 – (0)228 – 82300 – 148


Posts & mentions

17. February 2022

Biograil Secures Seed 2 Funding for Oral Delivery Device for Biologics

COPENHAGEN, DENMARK, Jan 17th, 2022 – Biograil ApS, a Copenhagen based biotech company developing a unique oral device for delivery of biologics that would otherwise be injected, announced the closing of a Seed 2 funding of 3.2 million Euro. The Round was led by Danish Megatrend Invest a/s with strong support from other prior investors including Verve Ventures, a Swiss Investment group and Sanner Ventures, a German family office. Evonik Venture Capital participated as a new investor. Ev
31. January 2022

Dräger AG Invests in Digital Health Startup GWA Hygiene

Lübeck and Stralsund, Germany, 31st of January 2022 – International leader in medical and safety technology, Dräger AG (Lübeck, Germany) and digital health startup GWA Hygiene (Stralsund, Germany) announced today that Dräger will become GWA Hygiene’s newest investor. GWA Hygiene has developed an electronic monitoring system for hand hygiene in hospitals. Before the current financing round, it attracted investments from other well-known funders in Germany, including venture capital fi
11. January 2022

Pantherna Therapeutics secures EUR 4.0 Mio. follow-on financing to advance its therapeutic mRNA development programs   

Hennigsdorf, January 11, 2022 - Pantherna Therapeutics today announces the successful completion of a follow-on financing round totaling EUR 4.0 Mio. led by existing investors Riesner Verwaltungs GmbH and High-Tech Gründerfonds. The proceeds of this round will be used to accelerate preclinical development activities for its lead program PAN004, an mRNA-based therapeutic for Acute Respiratory Distress Syndrome (ARDS).   ARDS causes a life-threatening damage to the lungs induced by an
14. December 2021

Post-merger integration as a key factor for successful acquisitions  

An acquisition is far from over with the signing of a contract – what then follows is the important process of integration. This is why High-Tech Gründerfonds (HTGF) is offering a think tank on this topic at the High-Tech Partnering Conference in February. The aim of the think tank is to discuss the topic with experts from different viewpoints. In this interview, Anke Caßing and Axel Nitsch, both princip
7. December 2021

Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

Series A round led by Pontifax and includes new and existing investorsLead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicityStrategy is to become a dominant ADC developer Duisburg, Germany, 7 December 2021 - Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces that it has closed an €87 million series A financing round. T
26. April 2021

PreComb Therapeutics AG secures CHF 2.2 Mio seed financing to advance personalized medicine for cancer patients

PreComb develops the next generation point-of-care technology for patient-specific profiling of cancer therapies PreComb Therapeutics today announced the successful completion of the seed financing round led by Kinled Austria, the High-Tech Gründerfonds and FiveT capital, in addition to participations from other investors. Patrick Aisher, managing partner at Kinled Austria, joined the company’s board of directors. The seed funding will help advance the proprietary 3D3 Technol
17. February 2021

Angiolutions’ novel vascular implant defuses the abdominal ticking time bomb

The award-winning team of the medtech startup Angiolutions successfully secured its seed financing round with High-Tech Gründerfonds, FRIBA Investment and NBank Capital. Based on the founders’ research, the company aims to prevent the deadly progression of small abdominal aortic aneurysms. We are thrilled to work with a strong investor syndicate enabling the successful completion of our critical R&D steps.Dr. Uwe Raaz and Dr. Isabel N. Schellinger, founders of Angiolutions
3. December 2020

Lymphatica Medtech raises seven-digit Series A round

LYMPHATICA Medtech, a vascular medical device development start-up, closes a seven-digit financing round to advance clinical validation aiming at revolutionizing the treatment of chronic lymphoedema. The investment round, led by High-Tech Gründerfonds, was joined by business angels, the EIT health (European Institute of Innovation and Technology) and existing investors, including LIVEventures. The Company also announces the appointment of Laurent Duhoux (ex VP New Technology at Edwards L
25. November 2020

Emergence Therapeutics Announces a Bumped-up Follow-on Seed Round Financing

Financing enables company to embark on additional targets and expand ADC technology reach Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, announces that is has closed a Bumped-up Follow-on Seed Round Financing from a syndicate of leading European investors comprising Bpifrance through its InnoBio 2 fund, Gründerfonds Ruhr, Heidelberg Pharma Research GmbH, High-Tech Gründerf
4. August 2020

High-tech firm from Singen, Germany, alongside HTGF (High-Tech Gründerfonds) and MBG co-invest: stimOS GmbH wins WEFA as strategic partner

WEFA Inotec GmbH (WEFA) – a German market leader in extrusion tooling, precision technology and CVD coatings - became a Series A investor in stimOS GmbH (stimOS), a South-Germany-based medical technology company: Despite the Covid-19 turbulent times, uncertainty and unknown entrepreneurial risks, stimOS was able to acquire substantial funding to allow further company expansion. The investment will be used to turn the patented "Mimicking Bone Technology (MBT)" into an internationally indust